§ 01 Overview
Overview
ADNP-derived microtubule-stabilizing octapeptide. Phase 2/3 PSP trial failed primary endpoint; orphan drug designation retained for ADNP syndrome.
PSP Phase 2/3 (Boxer 2014) failed primary. Continuing development in ADNP syndrome.
§ 02 Mechanism
Mechanism of action
Davunetide (NAPVSIPQ) is the active fragment of Activity-Dependent Neuroprotective Protein (ADNP). It binds EB1/EB3 to stabilize microtubules and reduces tau hyperphosphorylation.
- 01Microtubule stabilization
- 02Tau reduction in preclinical models
- 03Orphan designation for ADNP syndrome
§ 03 Dosing
Dosing protocol
Standard Protocol
- Dose Range
- 5 – 30 mg per dose (trial)
- Route
- Intranasal
- Frequency
- Daily
- Cycle
- Trial-dependent
§ 04 Evidence
Evidence & research
PSP Phase 2/3 (Boxer 2014) failed primary. Continuing development in ADNP syndrome.
FDA Status
Not FDA-approved. FDA Orphan Drug Designation for ADNP syndrome.
§ 06 News
In the news
8 articles from the last 12 months · updates hourly
NAP of the Day: Today’s NAPs Table of horse racing tips across the UK & Ireland - Paddy Power
NAP of the Day: Today’s NAPs Table of horse racing tips across the UK & Ireland Paddy Power
Newsboy's horse racing selections for Monday's four meetings, including Ayr nap - The Mirror
Newsboy's horse racing selections for Monday's four meetings, including Ayr nap The Mirror
Nap of the Day: John & Thady Gosden’s handicap debutante can shine at Windsor - Betfred Insights
Nap of the Day: John & Thady Gosden’s handicap debutante can shine at Windsor Betfred Insights
There’s a good reason for an afternoon snooze - Sudbury Star
There’s a good reason for an afternoon snooze Sudbury Star
Visit a museum to help slow aging, nap between 1 and 3 p.m. and uncross your legs — plus 6 more health tips to help you have a great week - Yahoo Health
Visit a museum to help slow aging, nap between 1 and 3 p.m. and uncross your legs — plus 6 more health tips to help you have a great week Yahoo Health
Today’s Lucky 15 Horse Racing Tips From Expert Andy Newton (Sunday 19th July) “Side With Curragh NAP” - Read Horse Racing
Today’s Lucky 15 Horse Racing Tips From Expert Andy Newton (Sunday 19th July) “Side With Curragh NAP” Read Horse Racing
Adorable baby elephant cuddles plush toy during nap - Yahoo News New Zealand
Adorable baby elephant cuddles plush toy during nap Yahoo News New Zealand
'She's been winning without breaking sweat' - Templegate's Sunday NAP - The Sun
'She's been winning without breaking sweat' - Templegate's Sunday NAP The Sun
§ 07 Sourcing
Sourcing & supply
Regulatory status
Investigational, no compounding path
Currently in active clinical trials. No compounding pathway. No brand product. The only US channels are RUO vendors that the FDA has targeted with warning letters. Assume any sourcing carries significant regulatory and quality risk.
No suppliers in our directory currently stock this compound. For investigational or research-only compounds, legitimate channels may not exist outside clinical trials.
Browse full supplier directory§ 09 Safety
Safety & side effects
Side effects
- 01Nasal irritation
- 02Headache
Contraindications
None specified.
§ 10 Questions
Davunetide (NAP) FAQ
- What is Davunetide (NAP)?
- ADNP-derived microtubule-stabilizing octapeptide. Phase 2/3 PSP trial failed primary endpoint; orphan drug designation retained for ADNP syndrome. Davunetide (NAPVSIPQ) is the active fragment of Activity-Dependent Neuroprotective Protein (ADNP). It binds EB1/EB3 to stabilize microtubules and reduces tau hyperphosphorylation.
- What is Davunetide (NAP) used for?
- Reported uses include microtubule stabilization, tau reduction in preclinical models, and orphan designation for adnp syndrome. Evidence strength is rated Clinical — see the evidence section for detail.
- How is Davunetide (NAP) dosed?
- Commonly referenced dosing is 5 – 30 mg per dose (trial), typically daily, administered Intranasal. This is educational reference only; consult a licensed clinician before use.
- What are the side effects of Davunetide (NAP)?
- Commonly reported side effects include nasal irritation and headache. This list is not exhaustive.
- Is Davunetide (NAP) legal?
- Currently in active clinical trials. No compounding pathway. No brand product. The only US channels are RUO vendors that the FDA has targeted with warning letters. Assume any sourcing carries significant regulatory and quality risk. FDA status: Not FDA-approved. FDA Orphan Drug Designation for ADNP syndrome..
§ 11 References
Selected references
- 01
Boxer — PSP Phase 2/3
PMID: 24873720 (NCT01110720)
- 02
Gozes Transl Psychiatry 2023
PMID: 37845203